{"id":1742,"date":"2026-04-15T13:49:37","date_gmt":"2026-04-15T13:49:37","guid":{"rendered":"http:\/\/www.ayercut.com\/index.php\/2026\/04\/15\/cannabis-legalization-spurs-innovation-but-not-always-in-ways-that-benefit-patients-or-public-health\/"},"modified":"2026-04-15T13:49:37","modified_gmt":"2026-04-15T13:49:37","slug":"cannabis-legalization-spurs-innovation-but-not-always-in-ways-that-benefit-patients-or-public-health","status":"publish","type":"post","link":"http:\/\/www.ayercut.com\/index.php\/2026\/04\/15\/cannabis-legalization-spurs-innovation-but-not-always-in-ways-that-benefit-patients-or-public-health\/","title":{"rendered":"Cannabis legalization spurs innovation, but not always in ways that benefit patients or public health"},"content":{"rendered":"
Even after legalization, researchers face significant barriers to studying cannabis.<\/span> Visoot Uthairam\/Moment via Getty Images<\/a><\/span><\/figcaption><\/figure>\n

Innovation in health care saves lives. But not all health innovations have enough evidence to actually benefit patients. <\/p>\n

Barriers to innovation are often higher in illicit or restricted markets, including cannabis<\/a>, stem cells<\/a> and cryptocurrencies<\/a>. Researchers face higher costs, limited access to raw materials and data, and stricter regulations. <\/p>\n

Cannabis illustrates a particularly confusing tension between regulatory restrictions on one hand and research and innovation on the other. <\/p>\n

While the U.S. federal government still classifies cannabis as having \u201cno accepted medical use<\/a>,\u201d many states have legalized it for medical or recreational use. Meanwhile, the Department of Health and Human Services obtained a cannabis-related patent in 2003<\/a> covering potential medical uses of cannabis compounds for protecting the brain from damage or degeneration. The patent was exclusively licensed for commercialization.<\/p>\n

Research and innovation on cannabis<\/a> can take many forms. Clinical trials may study cannabis products as medical treatments, the effects of cannabis on its users, or factors related to abuse and dependence. Meanwhile, cannabis-related patents can be filed for wide-ranging purposes, such as chemical formulations, methods for production or new consumer products like edibles, beverages or vaporizers. <\/p>\n

But do these innovations actually benefit consumers and patients?<\/p>\n

\"Hand<\/a>
The complex legal landscape of cannabis makes research and regulation difficult.<\/span> James MacDonald\/Bloomberg<\/a><\/span> <\/figcaption><\/figure>\n

We are<\/a> economists studying<\/a> how institutional changes<\/a> affect innovation<\/a> in different markets. Our recently published research<\/a> found that legalization of recreational cannabis use appears to spur innovation, but primarily in ways that expand commercial opportunities rather than scientific understanding or health benefits for patients. <\/p>\n

Cannabis\u2019 evolving legality in the US<\/h2>\n

Cannabis is a plant<\/a> that contains chemical compounds called cannabinoids<\/a>. One such compound, tetrahydrocannabinol, or THC, produces psychoactive effects, while another compound called cannabidiol, or CBD, is often used to relieve anxiety and pain. However, there has been insufficient evidence<\/a> on how effective cannabis products are in treating medical conditions, as well as a lack of consistent medical and dosing guidance. <\/p>\n

At the federal level in the U.S., cannabis has been classified as a Schedule I drug<\/a> for over a half-century. This classification indicates that the federal government considers cannabis to have a high potential for abuse and no accepted medical use. <\/p>\n

As a Schedule I drug, there are significant restrictions on cannabis research<\/a>. Researchers who seek to conduct cannabis-related clinical trials must obtain approval from both the Food and Drug Administration and the Drug Enforcement Administration, a process that can take over a year. They are also limited to using select varieties of cannabis obtained from federally authorized cannabis suppliers, and are generally prohibited from studying products available in state-authorized markets. <\/p>\n